Recently, Dorayshield successfully exported $20,000 worth of CF-18 tungsten alloy radiation shielding containers to a New Zealand medical equipment supplier, marking the official entry of the company's high-quality radiation protection products into the New Zealand market.
Dorayshield has designed and manufactured the CF-18 tungsten alloy radiation shielding container as one of the core products in medical protection. The CF-18 container provides 40% more protection from medical radiation, including X-rays and gamma rays, compared to conventional lead containers. In addition, the CF-18 container has a more advanced multi-layered construction. As a result, the CF-18 container construction weighs 15% less compared to counterpart products; the 15% reduction in weight improves container portability by medical professionals and staff. The New Zealanders' customers compared multiple suppliers globally and chose Dorayshield due to the CF-18’s excellent radiation shielding capacity, corrosion resistance, seal integrity, and the overall quality of CF-18..
This $20,000 order is the result of Dorayshield's long-term commitment to the medical radiation protection field and its active expansion into overseas markets. In recent years, the company has consistently prioritized "protecting medical radiation safety" and continuously upgraded its radiation protection product technology. Product specifications have been refined to address the differences in standards across different national medical markets (for example, the CF-18 model is a classic model suitable for small and medium-sized medical institutions). Furthermore, the company has established an efficient foreign trade service system, thoroughly researching medical device certification processes in various countries to provide customers with comprehensive support from product selection to customs clearance. Dorayshield's radiation protection products have already entered the medical markets of multiple countries, and their arrival in New Zealand further strengthens the company's presence in Oceania.
For Dorayshield, this export to New Zealand represents more than just securing an order; it also strengthens the company's brand recognition in the international medical protection market. In the future, the company will take this cooperation as an opportunity to continue to pay attention to the development needs of the medical industry in New Zealand and Oceania, increase investment in the research and development of radiation protection products, and launch more customized solutions suitable for different scenarios; at the same time, deepen the construction of overseas channels, and through participating in international medical exhibitions and cooperating with local distributors, etc., let more high-quality radiation protection products serve global medical institutions, promote the safe development of the global nuclear medicine field, and promote higher-quality growth of the company's foreign trade business.
